Clinical Trial Update: Pembrolizumab for Advanced NSCLC and PS 2-3 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab for advanced non-small cell lung cancer with performance status 2-3 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING